Literature DB >> 35291516

Variation in COVID-19 Disease Severity and Clinical Outcomes Between Different ABO Blood Groups.

Diyaa H Bokhary1, Nidal H Bokhary1, Lamees E Seadawi1, Ahlam M Moafa2, Hashim H Khairallah3, Abdullah A Bakhsh1.   

Abstract

The primary objective of this study was to explore whether coronavirus disease 2019 (COVID-19) severity and outcomes varied between different ABO blood groups. This retrospective study included 363 COVID-19 confirmed patients who had their blood group recorded in the hospital medical records, from March to June 2020. Data representing demographics, clinical features, vital signs, laboratory findings, and COVID-19 outcomes were collected. Multivariate logistic regression was used for analysis and the results were adjusted for sociodemographic, clinical, and laboratory variables. The patients' mean age was 50 ± 17.8 years. Of the 363 patients, 30% were blood group A, 22.3% were blood group B, 8.8% were blood group AB, and 38.8% were blood group O. Bivariate analysis showed that patients with blood group AB were more likely to be free of any medical disease (65.6%) compared to other blood groups (p = 0.007). Fever was the most common presenting complaint (66.7%), and it did not significantly vary with changes in ABO blood groups (p = 0.230). Regarding laboratory characteristics, only C-reactive protein (CRP) levels were significantly associated with the blood groups, with high levels seen in blood groups A, B, and O (p = 0.036). In multivariate analysis, variations in emergency department (ED) disposition, requirement of intensive care unit care, and requirement of mechanical ventilation were not statistically significant among the different ABO blood groups. Furthermore, no correlation was found between hospital death and the different ABO blood groups. In conclusion, COVID-19 is most prevalent among patients with blood group O and least prevalent among those with blood group AB. No particular blood group had worse COVID-19 disease severity and outcomes than other blood groups. Therefore, we believe that ABO blood grouping should not be used as a major assessment tool for COVID-19 disease severity and outcome, and other known risk factors should be investigated.
Copyright © 2022, Bokhary et al.

Entities:  

Keywords:  abo blood group; coronavirus; covid 19; outcome; severity

Year:  2022        PMID: 35291516      PMCID: PMC8896246          DOI: 10.7759/cureus.21838

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  28 in total

1.  The effect of ABO blood group on the diagnosis of von Willebrand disease.

Authors:  J C Gill; J Endres-Brooks; P J Bauer; W J Marks; R R Montgomery
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

Review 2.  Sexual Dimorphism in Innate Immunity.

Authors:  Sébastien Jaillon; Kevin Berthenet; Cecilia Garlanda
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

Review 3.  Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.

Authors:  Alaa Badawi; Seung Gwan Ryoo
Journal:  Int J Infect Dis       Date:  2016-06-21       Impact factor: 3.623

4.  Potential association of COVID-19 and ABO blood group: An Indian study.

Authors:  Iti Garg; Swati Srivastava; Vikas Dogra; Mona Bargotya; Sonali Bhattar; Utkarsh Gupta; Shruti Jain; Javid Hussain; Anju A Hembrom; Nilanjana Ghosh; Vinay Kumar; Bhuvnesh Kumar; Rajeev Varshney; Lilly Ganju
Journal:  Microb Pathog       Date:  2021-06-01       Impact factor: 3.738

5.  ABO blood group. Related investigations and their association with defined pathologies.

Authors:  Ursula Jesch; P Christian Endler; Beatrix Wulkersdorfer; Heinz Spranger
Journal:  ScientificWorldJournal       Date:  2007-08-10

6.  Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis.

Authors:  Bing-Bing Wu; Dong-Zhou Gu; Jia-Ning Yu; Jie Yang; Wang-Qin Shen
Journal:  Infect Genet Evol       Date:  2020-07-30       Impact factor: 3.342

7.  Blood type and outcomes in patients with COVID-19.

Authors:  Christopher A Latz; Charles DeCarlo; Laura Boitano; C Y Maximilian Png; Rushad Patell; Mark F Conrad; Matthew Eagleton; Anahita Dua
Journal:  Ann Hematol       Date:  2020-07-12       Impact factor: 3.673

8.  C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19.

Authors:  Milad Sharifpour; Srikant Rangaraju; Michael Liu; Darwish Alabyad; Fadi B Nahab; Christina M Creel-Bulos; Craig S Jabaley
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

9.  The potential use of ABO blood group system for risk stratification of COVID-19.

Authors:  Antoine Fakhry AbdelMassih; Reham Mahrous; AbdelFattah Taha; Alaa Saud; Aliaa Osman; Bishoy Kamel; Elaria Yacoub; Esraa Menshawey; Habiba-Allah Ismail; Lina Aita; Maria Dous; Marina Saad; Mariam AbdelAziz; Mario Zaghar; Noura Shebl; Nadine El-Husseiny; Nourhan Fahmy; Nouran Hegazy; Omar Khalid; Osama Saad; Peter Afdal; Rahma Menshawey; Reem Husseiny; Sandra Sherien; Sara Salama; Salma Gad; Sajjad Ali; Sayid Maalim; Sarah Ismail; Yara ElHefnawi; Youstina Aziz; Raghda Fouda
Journal:  Med Hypotheses       Date:  2020-10-09       Impact factor: 1.538

10.  Emergency room comprehensive assessment of demographic, radiological, laboratory and clinical data of patients with COVID-19: determination of its prognostic value for in-hospital mortality.

Authors:  Marco Gatti; Marco Calandri; Andrea Biondo; Carlotta Geninatti; Clara Piatti; Irene Ruggirello; Ambra Santonocito; Sara Varello; Laura Bergamasco; Paolo Bironzo; Adriana Boccuzzi; Luca Brazzi; Pietro Caironi; Luciano Cardinale; Rossana Cavallo; Franco Riccardini; Giorgio Limerutti; Andrea Veltri; Paolo Fonio; Riccardo Faletti
Journal:  Intern Emerg Med       Date:  2021-03-08       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.